Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Akero jumps on Nash

<< Previous

Bullboard Posts

Next >>

Comment by juniper88on Mar 04, 2024 10:14am

97 Views

Post# 35913087

RE:RE:RE:Akero jumps on Nash

My question is why PL was never able to make any kinda deal on getting a Phase 3 or even a Phase 2/3 started.

I know some here are now saying that it will happen once F8 is approved. But is F8 is that important (and yes, I believe it is) how did they manage to mess that up?? They didn't realize the importance to make sure the application was done absolutely perfect.

The imcompetence of this company has been astounding of the last several years.

I am afraid all we are left with now is the TH1902 lottery ticket. And if this fails, don't expect PL or the chairwoman to leave. Where else do you think he'll be able to get a $2 million/year job like this?

scarlet1967 wrote:

palinc2000 wrote: I read Nash bit its MASH !! LOL

palinc2000 wrote: https://seekingalpha.com/news/4075165-akero-stock-jumps-as-lead-drug-shows-added-fibrosis-improvement-in-mash-patients

Fatty liver disease is now called steatitic(fat build up) liver disease or SLD. Nonalcoholic fatty liver disease (NAFLD) is now called metabolic dysfunction-associated steatotic liver disease (MASLD). Metabolic dysfunction-associated steatohepatitis (MASH) has replaced NASH.

It took them a while to change the names but it shows although (formerly called )NAFLD and NASH are heterogeneous diseases with several causes the metabolic causes are the main reasons for the conditions. As for Akero there was an improvement between results after 36 weeks and now 96 weeks. It shows once again MASH also called silent killer is progressing slowly and the any treatment will take time reversing the damages.

It hard to resist not mentioning once again Tesamorelin improves the metabolic syndrome.